• Explore /
  • Poster
  • / GOBLET: A phase 1/2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic gastrointestinal cancers exploring treatment combinations with pelareorep and atezolizumab.

GOBLET: A phase 1/2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic gastrointestinal cancers exploring treatment combinations with pelareorep and atezolizumab.

Abstract Poster

Authors

Dirk Arnold

Dirk Arnold

Asklepios Tumorzentrum Hamburg, AK Altona, Hamburg, Germany

Dirk Arnold , Maike Collienne , Grey A Wilkinson , Houra Loghmani , Thomas Charles Heineman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

2020-003996-16

DOI

10.1200/JCO.2022.40.4_suppl.TPS216

Abstract #

TPS216

Poster Bd #

Q1

Abstract Disclosures

Similar Posters

First Author: Dirk Arnold

First Author: Timothy Jay Price

First Author: Jin Li

First Author: Amin Nassar